PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32138474-3 2020 Metformin can be used safely when the estimated glomerular filtration rate (eGFR) is >= 45 mL/min/1.73 m2. Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 94-99 32138474-4 2020 If the eGFR is between 30 and 44 mL/min/1.73 m2, metformin treatment should not be started. Metformin 49-58 CD59 molecule (CD59 blood group) Homo sapiens 36-41 32138474-6 2020 Metformin is contraindicated when the eGFR is < 30 mL/min/1.73 m2. Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 54-59 32138474-8 2020 During procedures involving intravenous administration of ICM, metformin should be discontinued starting the day of the procedures and up to 48 hours postprocedures if the eGFR is < 60 mL/min/1.73 m2. Metformin 63-72 CD59 molecule (CD59 blood group) Homo sapiens 188-193 30326091-0 2018 Metformin use was linked to hospitalization for acidosis at 6 y only in patients with eGFR < 30 mL/min/1.73 m2. Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 102-107 32097995-3 2020 Metformin can be used safely when the estimated glomerular filtration rate (eGFR) is >=45 mL/min/1.73 m2. Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 93-98 32097995-4 2020 If the eGFR is between 30 and 44 mL/min/1.73 m2, metformin treatment should not be started. Metformin 49-58 CD59 molecule (CD59 blood group) Homo sapiens 36-41 32097995-6 2020 Metformin is contraindicated when the eGFR is <30 mL/min/1.73 m2. Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 53-58 32097995-8 2020 During procedures involving intravenous administration of ICM, metformin should be discontinued starting the day of the procedures and up to 48 hours post-procedures if the eGFR is <60 mL/min/1.73 m2. Metformin 63-72 CD59 molecule (CD59 blood group) Homo sapiens 188-193 21435929-8 2011 Renal complications were not monitored carefully enough (missing value for albuminuria: 42%; -4.5 points), and 46% of those with a glomerular filtration rate less than 60 mL/min/1.73 m2 were taking metformin. Metformin 198-207 CD59 molecule (CD59 blood group) Homo sapiens 174-179 24842984-5 2014 Compared with nonusers, risk of lactic acidosis or elevated lactate concentrations in current metformin users was significantly associated with a renal function <60 mL/min/1.73 m(2) (adjusted HR 6.37 [95% CI 1.48-27.5]). Metformin 94-103 CD59 molecule (CD59 blood group) Homo sapiens 171-176 24842984-7 2014 CONCLUSIONS: Our study is consistent with current recommendations that the renal function of metformin users should be adequately monitored and that the dose of metformin should be adjusted, if necessary, if renal function falls below 60 mL/min/1.73 m(2). Metformin 161-170 CD59 molecule (CD59 blood group) Homo sapiens 241-246 29435189-2 2018 The aim of this study was to evaluate the effect of continuous metformin treatment in patients with type 2 diabetes mellitus (DM) and moderate chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) 30-0 ml/min/1.73 m2) on renal function. Metformin 63-72 CD59 molecule (CD59 blood group) Homo sapiens 225-230 27330129-6 2016 However, there have been millions of people exposed to metformin for many years, many of them with serum creatinine values at or close to 1.5 mg/dL with estimated glomerular filtration rates (eGFRs) much below 60 mL/min/1.73 m(2) who have not developed lactic acidosis. Metformin 55-64 CD59 molecule (CD59 blood group) Homo sapiens 216-221 26705203-7 2015 The corresponding tendency of higher anion gap in metformin users with the estimated glomerular filtration rate >60 mL/min/1.73 m was also observed. Metformin 50-59 CD59 molecule (CD59 blood group) Homo sapiens 122-127 26338686-8 2015 Prevalence of eGFR <60 mL/min/1.73 m(2) among metformin initiators was 9.0% in Denmark and 25.2% in the UK. Metformin 49-58 CD59 molecule (CD59 blood group) Homo sapiens 29-34 26338686-9 2015 In contrast, prevalence of eGFR values <30 mL/min/1.73 m(2) among metformin initiators was 0.3% in Denmark and 0.4% in the UK. Metformin 69-78 CD59 molecule (CD59 blood group) Homo sapiens 49-54 26338686-12 2015 The proportion of patients continuing metformin use, even after a first decline brought the eGFR below 30 mL/min/1.73 m(2), was 44% in Denmark and 62% in the UK. Metformin 38-47 CD59 molecule (CD59 blood group) Homo sapiens 109-114 23755710-2 2013 Metformin, the first choice oral glucose-lowering agent, is classically contraindicated in case of chronic kidney disease of stages 3-5 (creatinine clearance < 60 ml/min/1.73 m2), because of a risk of accumulation of the biguanide that may lead to lactic acidosis. Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 169-174 24047401-6 2013 AMP-activated protein kinase (AMPK) activators such as resveratrol, AICAR and metformin protected endothelial cells against complement-mediated cytotoxicity through the increase in CD55, CD59, haem oxygenase-1 (HO-1) and ferritin heavy chain (ferritin H) genes, all of which were attenuated by AMPKalpha knock-down. Metformin 78-87 CD59 molecule (CD59 blood group) Homo sapiens 187-191 20977579-7 2010 RESULTS: At the University of Chicago Diabetes Center, 36 of 234 (15.3%) patients with an eGFR of <60 ml/min/1.73 m(2) were receiving metformin. Metformin 137-146 CD59 molecule (CD59 blood group) Homo sapiens 108-113 20977579-8 2010 Data from NHANES, age >18 years and eGFR <60 ml/min/1.73 m(2) showed that Blacks with advanced nephropathy were three times more likely to receive metformin. Metformin 153-162 CD59 molecule (CD59 blood group) Homo sapiens 54-59 20977579-9 2010 CONCLUSIONS: We conclude that metformin utilization occurs with a higher frequency than predicted by serum creatinine in people with eGFR <60 ml/min/1.73 m(2) . Metformin 30-39 CD59 molecule (CD59 blood group) Homo sapiens 148-153 2272714-4 1990 They received metformin as the sole therapy when possible (sulfonylureas were discontinued in 9 cases) at a dosage of either 850 mg or 1,700 mg/day dependent on creatinine clearance values of 30-60 ml.min-1 (n = 11) and greater than 60 ml.min-1 (n = 13), respectively. Metformin 14-23 CD59 molecule (CD59 blood group) Homo sapiens 201-206 11118008-6 2000 Metformin reduced that rate by 24% (to 0.53 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/- 0.9 mmol/l, P = 0.0002). Metformin 0-9 CD59 molecule (CD59 blood group) Homo sapiens 68-74 8412779-5 1993 Fasting hepatic glucose production (HGP) was also significantly decreased following metformin therapy (1.98 +/- 0.13 v 2.41 +/- 0.20 mg.kg-1 x min-1, P < .02), whereas fasting insulin and C-peptide concentrations remained unaltered. Metformin 84-93 CD59 molecule (CD59 blood group) Homo sapiens 143-148